A randomized phase III trial of exemestane versus anastrozole in postmenopausal women with receptor positive primary breast cancer

Mise à jour : Il y a 4 ans
Référence : EUCTR2005-001893-28

Femme Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

To compare event free survival (EFS) between postmenopausal women treated with exemestane or anastrozole as adjuvant therapy.


Critère d'inclusion

  • Post-menopausal women, histologically or cytologically confirmed, receptor-positive, adequately excised, primary breast cancer